Status:
COMPLETED
Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
HealthCore, Inc.
Conditions:
COPD
Eligibility:
All Genders
40+ years
Brief Summary
This study is intended to evaluate treatment effectiveness of BFC compared to FSC in COPD patients new to ICS/LABA combination therapy.
Eligibility Criteria
Inclusion
- Continuous health plan enrollment for 12 months before and after index Rx, at least one prescription for BFC or FSC during intake period, naive to ICS/LABA therapies in year prior to first prescription claim, COPD diagnosis, aged 40 or over at time of first prescription.
Exclusion
- ICS/LABA combination during pre-index period, patients with a claim for BFC and FSC on the same day, patients diagnosed with cancer, patients with long-term OCS medication use during pre-index period.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2014
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT01921127
Start Date
August 1 2013
End Date
March 1 2014
Last Update
February 3 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.